Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| X4 Pharmaceuticals, IncXFOR · Entity 5638 | Director | January 01, 2026 | January 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
X4 Pharmaceuticals, Inc
Report date January 01, 2026 · Filed January 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.00 · Expires 2036-01-01 | Direct | 0 |
Reported balance
After 2026-01-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-01 · Grant · Acquired 110,000 · Balance 0 F1: The shares subject to the option shall vest in full upon stockholder approval of an increase in the share reserve under the Companys Amended and Restated 2017 Equity Incentive Plan at the Companys 2026 annual meeting of stockholders, subject to the Reporting Person continuing to provide services through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option shall vest in full upon stockholder approval of an increase in the share reserve under the Companys Amended and Restated 2017 Equity Incentive Plan at the Companys 2026 annual meeting of stockholders, subject to the Reporting Person continuing to provide services through such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 01, 2026 Filed Jan 5, 2026 21:06 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantStock Option (right to buy) · Derivative | 110,000 | $0.00 Strike: $4.00 | $0.00 |
DisclosureSEC source: 0001501697-26-000007 · wk-form4_1767647168.xml · derivative · entry 1 de Craecker Francoise · CIK 0001887843 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 110,000 shares Expires 2036-01-01 F1 · derivative.exercise_date: The shares subject to the option shall vest in full upon stockholder approval of an increase in the share reserve under the Companys Amended and Restated 2017 Equity Incentive Plan at the Companys 2026 annual meeting of stockholders, subject to the Reporting Person continuing to provide services through such date. Read SEC document |
| June 09, 2025 Filed Jun 10, 2025 20:30 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantCommon Stock | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-030503 · wk-form4_1749587436.xml · nonDerivative · entry 1 de Craecker Francoise · CIK 0001887843 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,722 F1 · shares: Represents restricted stock units (RSUs) granted to the Reporting Person as an annual award for service on the Board of Directors. The RSUs will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the Issuer's next annual meeting of stockholders, subject to continued board service through the applicable vesting date. The RSUs will vest in full upon the occurrence of a change in control of the Issuer. Read SEC document |
| June 10, 2024 Filed Jun 11, 2024 20:13 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantCommon Stock | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-027678 · wk-form4_1718136807.xml · nonDerivative · entry 1 de Craecker Francoise · CIK 0001887843 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,667 F1 · shares: Represents restricted stock units (RSUs) granted to the Reporting Person as an annual award for service on the Board of Directors. The RSUs will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the Issuer's next annual meeting of stockholders, subject to continued board service through the applicable vesting date. The RSUs will vest in full upon the occurrence of a change in control of the Issuer. Read SEC document |
| June 13, 2023 Filed Jun 14, 2023 20:57 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantCommon Stock | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-022090 · wk-form4_1686776222.xml · nonDerivative · entry 1 de Craecker Francoise · CIK 0001887843 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,667 F1 · shares: Represents restricted stock units (?RSUs?) granted to the Reporting Person as an annual award for service on the Board of Directors. The RSUs will vest in full on the earlier of (i) the one-year anniversary of the grant date or (ii) the Issuer?s next annual meeting of stockholders, subject to continued board service through the applicable vesting date. The RSUs will vest in full upon the occurrence of a change in control of the Issuer. Read SEC document |
| June 06, 2022 Filed Jun 27, 2022 20:16 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantCommon Stock | 6,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-018051 · wf-form4_165636096357790.xml · nonDerivative · entry 1 de Craecker Francoise · CIK 0001887843 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,667 F1 · shares: Represents an annual grant of restricted stock units ("RSUs") for service as a director to the Issuer. The RSUs will vest in two equal annual installments on June 6, 2023 and June 6, 2024, subject to the Reporting Person continuing to provide service to the Issuer through the applicable vesting date. F2 · balance_after: Represents unvested RSUs. Read SEC document |
| October 14, 2021 Filed Oct 18, 2021 20:15 UTC | X4 Pharmaceuticals, Inc XFOR · Entity 5638 | GrantStock Option (right to buy) · Derivative | 12,250 | $0.00 Strike: $5.37 | $0.00 |
DisclosureSEC source: 0001628280-21-020185 · wf-form4_163458811748496.xml · derivative · entry 1 de Craecker Francoise · CIK 0001887843 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,250 Underlying: Common Stock · 12,250 shares Expires 2031-10-13 F1 · derivative.exercise_date: 33.3333% of the shares subject to the option shall vest on October 14, 2022, with the remainder vesting thereafter in equal monthly installments of 2.7777% of the shares subject to the option until the 36-month anniversary of the date of the grant, subject to the Reporting Person's continued services as a director through each applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.